

STUYVER, et al.
Appl. No. 10/606,879
Attny. Ref.: 2551-123
Amendment
March 4, 2009

AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

Claims 1-14. (Canceled)

Claim 15. (Canceled)

16. (Currently Amended) The method according to claim [[15]]35, wherein the HBV genotype A specific target sequence in the HBsAg region is selected from the HBsAg region of the group consisting of SEQ ID NOs: 279-283.

Claim 17. (Canceled)

18. (Withdrawn – Currently Amended) The method according to claim 35 or claim 16any one of claims 15-17, characterized further by determining the presence or absence of HBV genotype B, wherein the probe(s) of step (iii) hybridize(s) specifically to a HBV genotype B specific target sequence in the HBsAg region.

19. (Withdrawn) The method according to claim 18, wherein the HBV genotype B specific target sequence is SEQ ID NO: 78, or the complement thereof.

20. (Withdrawn – Currently Amended) The method according to claim 35 or claim 16any one of claims 15-17, characterized further by determining the presence or absence of HBV genotype C, wherein the probe(s) of step (iii) hybridize(s) specifically to a HBV genotype C specific target sequence.

21. (Withdrawn) The method according to claims 20, wherein the HBV genotype C specific target sequence is selected from the group consisting of SEQ ID NO: 153, SEQ ID NO: 154 and SEQ ID NO: 204, or the complement thereof.

STUYVER, et al.
Appl. No. 10/606,879
Attny. Ref.: 2551-123
Amendment
March 4, 2009

22. (Withdrawn – Currently Amended) The method according to claim 35 or
claim 16any one of claims 15-17, characterized further by determining the presence or
absence of HBV genotype D, wherein the probe(s) of step (iii) hybridize(s) specifically to
a HBV genotype D specific target sequence.

23. (Withdrawn) The method according to claim 22, wherein the HBV genotype
D specific target is selected from the group consisting of SEQ ID NO: 165 and SEQ ID
NO: 208, or the complement thereof.

24. (Withdrawn – Currently Amended) The method according to claim 35 or
claim 16any one of claims 15-17, characterized further by determining the presence or
absence of HBV genotype E, wherein the probe(s) of step (iii) hybridize(s) specifically to
a HBV genotype E specific target sequence.

25. (Withdrawn) The method according to claim 24, wherein the HBV genotype
E specific target sequence is selected from the group consisting of SEQ ID NO: 172 and
SEQ ID NO: 213, or the complement thereof.

26. (Withdrawn – Currently Amended) The method according to claim 35 or
claim 16any one of claims 15-17, characterized further by determining the presence or
absence of HBV genotype F, wherein the probe(s) of step (iii) hybridize(s) specifically to
a HBV genotype F specific target sequence.

27. (Withdrawn) The method according to claim 26, wherein the HBV genotype
F specific target sequence is selected from the group consisting of SEQ ID NO: 186,
SEQ ID NO: 216 and SEQ ID NO: 219, or the complement thereof.

STUYVER, et al.
Appl. No. 10/606,879
Attny. Ref.: 2551-123
Amendment
March 4, 2009

28. (Currently Amended) The method according to claim 35 or claim 16any one of claims 15-17 wherein the primer is selected from the group consisting of SEQ ID NOs: 75-76, 94, 105, 112 and 134-135.

29. (Currently Amended) The method according to claim 35 or claim 16any one of claims 15-17 wherein step (iii) is a reverse hybridization step.

Claim 30. (Canceled)

31. (Withdrawn – Currently Amended) A probe ~~of about 5 to 50 nucleotides long~~ specifically hybridizing to a HBV genotype A specific target sequence in the HBsAg region of HBV, said target sequence being selected from the group consisting of SEQ ID NO: 77, SEQ ID NO: 140, SEQ ID NO: 148 and SEQ ID NO: 193, or the complement thereof.

32. (Withdrawn – Currently Amended) A composition comprising at least two probes ~~of about 5 to 50 nucleotides long~~ specifically hybridizing to a HBV genotype specific target sequence in the HbsAg region of HBV, said target sequence for genotype A being selected from the group consisting of SEQ ID NO: 77, SEQ ID NO: 140, SEQ ID NO: 148 and SEQ ID NO: 193, or the complement thereof; for genotype B being selected from the group consisting of SEQ ID NO: 78 and SEQ ID NO: 148, or the complement thereof; for genotype C being selected from the group consisting of SEQ ID NO: 80, SEQ ID NO: 153, SEQ ID NO: 154 and SEQ ID NO: 204, or the complement thereof; for genotype D being selected from the group consisting of SEQ ID NO: 80, SEQ ID NO: 165 and SEQ ID NO: 208, or the complement thereof; for genotype E being selected from the group consisting of SEQ ID NO: 80, SEQ ID NO: 172, SEQ ID

STUYVER, et al.
Appl. No. 10/606,879
Attny. Ref.: 2551-123
Amendment
March 4, 2009

NO: 177 and SEQ ID NO: 213, or the complement thereof; for genotype F being selected from the group consisting of SEQ ID NO: 177, SEQ ID NO: 216, SEQ ID NO: 219 and SEQ ID NO: 186, or the complement thereof.

Claim 33. (Canceled)

34. (Withdrawn – Currently Amended) An assay kit for diagnosing or monitoring HBV genotypes present in a biological sample comprising at least one of the probes according to claim [[30]]31, possibly optionally fixed to a solid support.

35. (new) A method for determining the presence or absence of HBV genotype A in a biological sample, comprising:

- (i) optionally releasing, isolating and/or concentrating the polynucleic acids present in the sample;
- (ii) optionally amplifying the HBsAg region, or part thereof, of the HBV gene present in said sample with at least one suitable primer pair;
- (iii) hybridizing the polynucleic acids of step (i) or (ii) with at least one nucleotide probe selected from the group consisting of a sequence of 5-17 nucleotides long which hybridizes specifically to SEQ ID NO 77, a sequence of 5-19 nucleotides long which hybridizes specifically to SEQ ID NO 140, and a sequence of 5-18 nucleotides long which hybridizes specifically to SEQ ID NO 193;
- (iv) detecting the hybrid(s) formed in step (iii);
- (v) inferring the HBV genotype present in said sample from the hybridization signal(s) obtained in step (iv).

36. (new) A method for determining the presence or absence of HBV genotype

A in a biological sample, comprising:

- (i) optionally releasing, isolating and/or concentrating the polynucleic acids present in the sample;
- (ii) optionally amplifying the HBsAg region, or part thereof, of the HBV gene present in said sample with at least one suitable primer pair, at least one of said primer pair being selected from the group consisting of SEQ ID NOs: 75-76, 94, 105, 112 and 134-135;
- (iii) hybridizing the polynucleic acids of step (i) or (ii) with at least one nucleotide probe of about 5 to 50 nucleotides long hybridizing specifically to a HBV genotype A specific target sequence in the HBsAg region of HBV;
- (iv) detecting the hybrid(s) formed in step (iii);
- (v) inferring the HBV genotype present in said sample from the hybridization signal(s) obtained in step (iv).

37. (new) The method according to claim 36, wherein the HBV genotype A specific target sequence is selected from the group consisting of SEQ ID NO: 77, SEQ ID NO: 140 and SEQ ID NO: 193, or the complement thereof.

38. (new) The method according to claim 35 wherein step (iii) is a reverse hybridization step.

39. (new) The method according to claim 36 wherein step (iii) is a reverse hybridization step.

STUYVER, et al.
Appl. No. 10/606,879
Attny. Ref.: 2551-123
Amendment
March 4, 2009

40. (new) The method according to claim 37 wherein step (iii) is a reverse hybridization step.